web analytics
0.3 C
Sunday, November 27, 2022

Comeback Time on Plandai Biotechnology Inc (OTCMKTS:PLPL)

Plandai Biotechnology Inc (OTCMKTS:PLPL) has been moving up steadily in recent days on accelerating volume since reversing off $0.011 lows. PLPL has fallen a long way since the multi dollar share price it used to trade for.

PLPL has a long history of big moves making a spectacular run back in early 2015 when pot stocks got hot and ruled the bb’s running from pennies to highs well over $3 a share.

Plandai Biotechnology Inc (OTCMKTS:PLPL) and its subsidiaries develop highly bioavailable, phytonutrient rich extracts which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. Plandaí Biotechnology, through its South African subsidiaries, controls every aspect of production, from growing specific raw materials such as green tea on its farms to producing its proprietary Phytofare(TM) extract, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process.

The manufacturing facility has also been engineered for citrus fruits and the recovery of limonoids. Targeted industries for the Company’s products include beverage, cosmeceutical, wellness, nutraceutical, anti-aging, and pharmaceutical.

PLPL products include Phytofare™ Catechin Complex, a water-soluble powder, Ph2™ Topical Catechin Complex, a topical cream that has Phytofare™ nano-entrapped in Pheroid™, Ph2™ Oral Catechin Complex, a gel tab version of Phytofare™ nano-entrapped in Pheroid™, suitable for oral consumption, and Ph2™ Liquid Catechin Complex, an oral version of Phytofare™ nano-entrapped in Pheroid™ in a liquid suspension, suitable for mixing into beverages and liquid medications.

Last year PLPL started two clinical trials. The first includes 35 participants and focuses on the depth of penetration of the company’s Phytofare™ Pheroid™ Catechin Complex to demonstrate that Plandaí’s product can be effectively used in topical creams to deliver Phytofare™ into target tissues. The second clinical trial includes 35 participants, and focuses on the anti-inflammatory properties of Plandaí’s Phytofare™ Pheroid™ Catechin Complex. The company’s goal is to show reduced redness and irritation in a topical application which will allow Phytofare™ to be used in various skin care products.

To Find out the inside Scoop on PLPL Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

Plandaí Biotechnology – Uruguay, SA, a wholly owned subsidiary of Plandaí Biotechnology, is currently the only company given authorization to grow cannabis and conduct medical research in Uruguay. Published research indicates that Plandaí’s proprietary extraction process should render the complete cannabinoid complex from the live plant while retaining the acid forms of THC, which are devoid of psychotropic effects. The result should be a highly bioavailable extract that retains all of the potential medical benefits of cannabis without the psychoactive properties. Plandaí intends to establish a pharmaceutical platform in once the initial scientific investigations have been successfully completed.

On August 25 PLPL announced it has reached an agreement in principal with North West University in South Africa, to begin human clinical trials on the island of Mauritius, a member of the SADC group of African countries, to determine the effectiveness of using Phytofare® catechin complex in regulating insulin levels in Type II Diabetes patients. North West University and the Company are finalizing the trial protocols which has a provisional start date of November 2016. Mauritius was selected as the trial site because, according to the World Health Organization and the International Diabetes Federation (IDF), the prevalence of Type II Diabetes in Mauritius in 2015 was a world-leading 16.28%. Worldwide as of 2013, 382 million people, or 8.3% of the adult population have diabetes, with Type II Diabetes making up about 90% of the cases. In 2014, the IDF estimated that diabetes resulted in 4.9 million annual deaths.

The proposed double-blind study will encompass 100 patients over 3 months, with a cross-over to the alternative treatment after 3 months, resulting in a total trial duration of 6 months. Compared to generic green tea extracts, Plandaí’s Phytofare® Catechin Complex has been clinically shown to deliver ten times greater levels of catechins to the blood plasma where they remain at therapeutic levels for over 24 hours.

We have a Monster Pick Coming. Subscribe Right Now!

Currently trading at a $3.2 million market valuation PLPL has minimal assets or revenues and a significant debt problem with $15 million in payables (that can lead to massive dilution) PLPL is an exciting Company known as the producer of the highly bioavailable Phytofare® catechin complex. The Company just reached an agreement to begin human clinical trials on the island of Mauritius, a member of the SADC group of African countries, to determine the effectiveness of using Phytofare® catechin complex in regulating insulin levels in Type II Diabetes patientsWe will be updating on PLPL when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with PLPL.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in PLPL either long or short and we have not been compensated for this article.

More articles


  1. Shocked by the fact that so many people are having diabetes. I’m eating diabetes curing diet to improve my health and reverse diabetes. So far I’m satisfied with the results. I actually read an article about diabetes curing diet and it seemed like the person had great success so I gave it a try. The article was very helpful to me — if you want to check it out yourself you can read it here http://curediabetespro.gq/


Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.